Patents by Inventor Toshihiro Mineta

Toshihiro Mineta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Patent number: 8273568
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the ?34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: September 25, 2012
    Assignee: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Publication number: 20040228841
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the &ggr;34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Application
    Filed: March 1, 2004
    Publication date: November 18, 2004
    Applicants: Georgetown University, MARTUZA et al.
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Publication number: 20040151697
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the &ggr;34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Application
    Filed: December 31, 2003
    Publication date: August 5, 2004
    Applicant: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Patent number: 6699468
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the &ggr;34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: March 2, 2004
    Assignee: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Replication-competent Herpes simplex virus mediates destruction of neplastic cells
    Patent number: 6139834
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the .gamma.34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: October 31, 2000
    Assignee: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Patent number: 5585096
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the .sub..gamma. 34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Grant
    Filed: June 23, 1994
    Date of Patent: December 17, 1996
    Assignee: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta